This bill mandates the Secretary of Veterans Affairs to report to Congress on the prevalence, support, and research efforts related to Amyotrophic Lateral Sclerosis (ALS) among veterans.
Jason Crow
Representative
CO-6
The Veterans with ALS Reporting Act requires the Secretary of Veterans Affairs to submit a comprehensive report to Congress on the prevalence of Amyotrophic Lateral Sclerosis (ALS) among veterans. This report must detail current support resources, identify gaps, and propose plans for reducing ALS incidence and improving clinical trial access for affected veterans. The VA will also be required to continuously track ALS rates using the CDC's existing registry.
The Veterans with ALS Reporting Act requires the Department of Veterans Affairs (VA) to get serious about Amyotrophic Lateral Sclerosis (ALS), often called Lou Gehrig’s disease, among former service members. Essentially, this bill mandates a comprehensive, data-driven deep dive into how ALS affects the veteran community and what the government is actually doing about it.
Within one year, the Secretary of Veterans Affairs must submit a detailed report to Congress, created in consultation with the Director of the Centers for Disease Control and Prevention (CDC). This isn't just a quick memo; it has to include an evaluation of how common ALS is among veterans, a description of all the support and resources the VA and CDC currently offer, and, critically, a description of any weaknesses found in those resources. If you're a veteran dealing with ALS right now, this is the part that matters—it forces the VA to look critically at where their support is falling short.
Beyond the basic evaluation, the bill pushes the VA toward concrete action. The required report must include two major plans. First, a plan for creating and testing methods intended to reduce the number of new ALS cases and the overall rate of the disease among veterans. This means moving beyond just treating the symptoms and into prevention and research. Second, the VA must detail a plan for how veterans receiving ALS care at VA clinics can easily join clinical trials and research sponsored by the VA. For veterans and their families, this could mean better access to cutting-edge treatments and a chance to contribute to finding a cure.
Perhaps the most important long-term provision is the mandate for continuous tracking. The VA must track the prevalence of ALS among veterans by utilizing the existing ALS registry and biorepository maintained by the CDC. This links the VA's data directly to a national system, ensuring a consistent and robust data set. This isn't a one-and-done report, either. The VA must send Congress an update to the initial report three years after the law is enacted, and then every three years after that, ensuring that the data collection and evaluation process remains a permanent fixture of VA operations. This ongoing requirement means the issue won't just fade away after the initial report is filed, providing continuous accountability and data to researchers and policymakers.